Despite a brief bounce, the price of Bitcoin is still below the pivotal $90,000 mark, which has become a significant resistance lately, capping upside attempts.Despite a brief bounce, the price of Bitcoin is still below the pivotal $90,000 mark, which has become a significant resistance lately, capping upside attempts.

Bitcoin Shows Rare Confluence In Network Growth And Risk Index – What It Means For BTC

2026/01/29 23:00
3 min read

Despite a brief bounce, the price of Bitcoin is still below the pivotal $90,000 mark, which has become a significant resistance lately, capping upside attempts. With recent signals from two key indicators, the slight upward push by the flagship asset may just be the beginning of another major rally.

Key Bitcoin Indicators Are Converging

Bitcoin’s price experienced a bounce on Wednesday, gradually reigniting bullish sentiment across the broader crypto market. It is worth noting that two closely watched indicators are now starting to portray the same story of a renewed bullish market trend.

Specifically, the shift is being showcased by the Bitcoin Network Growth and Risk Index. As outlined by the Bitcoin Vector, an institutional market-grade professional, on the X platform, these two crucial indicators are beginning to move in alignment, which is capable of shaping the crypto king’s next price trajectory in the short term.

In the past, the combination of Risk Index and Network Growth has often turned out to be a powerful leading indicator for BTC. This convergence points to a change toward a more balanced market environment where rising risk signals are no longer overpowering growing network activity.

When these key metrics synchronize, it frequently denotes a period of transition that may come before more long-term pricing trends. Currently, the chart shows a significant decline in network growth (1) and a high-risk environment (2), which typically leads to sustained bullish trends.

Bitcoin

With BTC traditionally being “late to the party,” the market may be looking at one of the most massive rallies ever recorded in years. In the meantime, these indicators provide a more comprehensive, data-driven understanding of the fundamental health of Bitcoin that goes beyond short-term price swings.

In another post, Bitcoin Vector shared that a significant bullish divergence is forming between BTC and the Relative Strength Index (RSI). The formation of this bullish divergence points to a possible shift in momentum beneath the surface.

Given that similar setups have historically generated over 10% returns on these timeframes, the expert claims that a return to the $95,000 price mark is becoming likely. However, the real signal lies in the confluence. If the market continues to increase in both Network Fundamentals and Liquidity while maintaining BTC Dominance, a major bullish reversal is probably about to begin.

BTC Whales And Retailers’ Activity Diverging

According to current market trends, Bitcoin retail investors are dumping their holdings while large holders or whales are steadily buying more BTC. CW, a market expert, noted that this divergence was observed ahead of the FOMC meeting. However, the brown whale is offloading a small portion of its BTC stash.

During the investors’ action, the BTC sell wall at the $90,000 level has vanished, whereas the sell wall at $86,000 is still active. Nonetheless, a new wall is developing at the $95,000 mark, and volatility will likely happen after 3 hours.

Bitcoin
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26